Answers are grounded in this paper and cite their sources.
COVID-19 patients are frequently coinfected by other microbial pathogens, adding to the severity of the cases and raising difficulty in the diagnosis, prognosis, and treatment. Pulmonary mucormycosis and invasive Aspergillosis are such life-threatening fungal infections. Risk factors include uncontrolled diabetes mellitus, hematological malignancies, solid organ transplantation, and chronic renal failure. Pulmonary emboli and pneumothorax have also been reported frequently in COVID-19 patients, especially in those who required invasive mechanical ventilation. Herein, we report four different cases of post COVID pulmonary complications. All four patients were evaluated with computed tomography thorax. Two patients had necrotizing pneumonia and sputum culture grew mucor and Aspergillus species, respectively. They were treated with intravenous antifungals. One patient had rifampicin-sensitive pulmonary tuberculosis (TB) and was started on antitubercular drugs. Both pulmonary mucormycosis and pulmonary TB patients had a segmental and subsegmental pulmonary embolism. They were managed with low-molecular-weight heparin. One patient had left pneumothorax, for which intercostal drainage was placed.
No takes yet. Share an insight, caveat, or question.
Palaninathan et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: